Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by ImmunoGen Inc.

ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating Results
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian Cancer
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2023 Operating Results
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Platinum-Resistant Ovarian Cancer
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2023 Operating Results
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Conference Call to Discuss Its 2022 Operating Results
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2022 Operating Results
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2022 Operating Results
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Research Collaboration with Oxford BioTherapeutics to Develop Novel Antibody-Drug Conjugates
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2022 Operating Results
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Reports Recent Progress and 2021 Financial Results
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Conference Call to Discuss Its 2021 Operating Results
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Appoints Mimi Huizinga, MD, as Senior Vice President and Head of Medical Affairs
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Proposed Public Offering of Common Stock
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Appoints Tracey L. McCain, Esq. to Its Board of Directors
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Appoints Kristen Harrington-Smith as Senior Vice President and Chief Commercial Officer
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
ImmunoGen Reports Recent Progress and Third Quarter 2021 Financial Results
From ImmunoGen Inc.
Via Business Wire
Tickers IMGN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.